Meloflex

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Meloflex

Quick Facts

Property Description
Active ingredient Meloxicam (single-ingredient product)
Form Tablet, Oral Suspension, Solution for Injection
Pharmacological class Non-steroidal anti-inflammatory drug (NSAID)
Common purpose Relief of pain, stiffness, and inflammation
Origin Synthetic substance (Oxicam derivative)

What Type of Medicine is Meloflex?

Meloflex is the proprietary name for a pharmaceutical preparation whose active ingredient is Meloxicam, which is classified as a Non-steroidal anti-inflammatory drug (NSAID). This synthetic substance belongs to the oxicam derivative subgroup, structurally related to Piroxicam, and is consistently manufactured as a single-ingredient product. Meloxicam is derived from the enolic acid chemical group, defining its unique position within its therapeutic classification.

The primary pharmacological class establishes the medication's core function: to exert both an anti-inflammatory effect and an analgesic effect. Meloxicam is a long-acting NSAID that is clinically recognized for its ability to ease discomfort and stiffness in chronic joint conditions.

Meloxicam's Forms and Differentiating Action

The pharmaceutical preparation of Meloxicam is available in multiple systemic dosage forms, ensuring flexible delivery to diverse patient populations. Common dosage forms include oral tablets, liquid oral suspension, and a sterile solution for injection for parenteral administration. This variety of forms helps support the management of inflammatory activity.

The drug's primary physiological action is as a preferential cyclooxygenase-2 (COX-2) inhibitor, which is the distinguishing feature of its efficacy profile. Unlike older, non-selective NSAIDs, which inhibit both COX-1 and COX-2 enzymes broadly, Meloxicam is designed to more selectively target the COX-2 enzyme, which is typically induced at sites of inflammation. This targeted approach helps reduce the prostaglandin synthesis that drives pain and swelling, confirming its value in the therapeutic classification for managing inflammatory conditions.

Regulatory References

  1. National Institutes of Health (NIH)
  2. NIH, LiverTox

What side effects are possible with Meloflex?

Possible side effects and safety information

The safety profile of Meloflex (Meloxicam) is formally established through regulatory documents, organizing potential events by frequency and the body system affected. As a Non-steroidal anti-inflammatory drug (NSAID), its safety profile includes considerations common to this class.


Officially Classified Adverse Reactions

Adverse reactions are classified based on the frequency documented in regulatory sources:

  • Common Reactions (occurring in ge 1/100 people): Frequently observed effects involve the Gastrointestinal system (e.g., dyspepsia, nausea, abdominal pain, diarrhea) and Nervous System (e.g., headache, dizziness). Generalized swelling (oedema) is also listed as common.
  • Uncommon Reactions (occurring in ge 1/1,000 people): These include changes in blood parameters (anaemia), vertigo, increased blood pressure, and documented abnormalities in liver and renal function tests.

Serious Adverse Reaction Statements

Regulatory authorities document the potential for serious, class-related events. These include potentially life-threatening Gastrointestinal Events, such as bleeding, ulceration, or perforation of the stomach or intestine. Furthermore, the label highlights the risk of Serious Cardiovascular Thrombotic Events, including the potential for myocardial infarction and stroke.

Contextual Safety Notes

Official regulatory documents note that the risk of serious cardiovascular thrombotic events may increase with the duration of use. Separately, the safety profile identifies older adults as a population at greater risk for serious gastrointestinal and cardiovascular adverse events. Safety constraints are formally established, restricting use in individuals with active gastrointestinal ulceration, severe hepatic impairment, or uncompensated heart failure.

Overdose and Emergency Response

Suspected overdose involving Meloflex requires seeking immediate medical attention, as officially documented in regulatory information. Manifestations of acute overdose may include gastrointestinal disturbances such as nausea, vomiting, epigastric pain, and gastrointestinal bleeding, alongside central nervous system effects like lethargy and drowsiness.

Overdose exposure carries the potential for severe, life-threatening outcomes. Official regulatory documents list complications including acute renal failure, hepatic dysfunction, hypertension, respiratory depression, convulsions, coma, and cardiac arrest. If these severe manifestations occur, emergency services must be contacted immediately, and the patient requires mandatory hospital monitoring and close observation.

Management of Meloflex overdose is symptomatic and supportive, as no specific antidote is known. Medical procedures, such as gastric lavage or the administration of activated charcoal, may be considered in a healthcare setting shortly after ingestion to limit systemic absorption. The regulatory profile notes that while symptoms are often reversible with supportive care, elderly patients and those with pre-existing renal or hepatic impairment face an increased risk of severe consequences following an overdose.

Therapeutic Uses of Meloflex

What Meloflex Treats: Main Uses and Benefits

Meloflex is relevant in contexts involving symptomatic relief across key inflammatory and pain-driven domains. Meloxicam is used in the management of chronic arthritis, with current indications that include osteoarthritis, rheumatoid arthritis, and juvenile rheumatoid arthritis, as well as post-operative pain.


Managing Chronic Pain, Stiffness, and Inflammation

Meloflex is commonly applied in the context of conditions characterized by periods of heightened symptoms. It is used for managing the symptom cluster that includes persistent joint pain, localized swelling, and physical stiffness that interferes with daily functioning.

“It provides a supportive therapeutic benefit, helping patients cope more steadily with symptom fluctuations.”

This relief is commonly considered helpful for adults with chronic conditions and for specific pediatric patients managing Juvenile Idiopathic Arthritis (JIA). Meloflex provides supportive relief when symptoms interfere with routine activities.

Quick Fact: Relief for Inflammation and Joint Pain


Acute and Perioperative Pain Support

This medication is relevant in clinical settings that involve acute or unstable symptom patterns, primarily for the management of acute moderate-to-severe pain and associated inflammation. It is often used during phases when symptoms become more noticeable, such as following surgical procedures (perioperative period) or during acute flares of musculoskeletal pain syndromes. In these situations, Meloflex provides temporary assistance in symptom stabilization, contributing to easing the overall symptom load during periods of heightened symptoms.

Regulatory References

  1. NIH LiverTox overview

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Meloflex — Official Regulatory Information

Meloflex (meloxicam) eligibility is strictly defined by regulatory guidelines based on age, physiological status, and underlying health conditions.

Eligibility scope Status as per Regulatory Labeling
Populations for whom use is allowed (as stated in label): Adults; Pediatric patients ge 2 years of age with Juvenile Rheumatoid Arthritis (JRA); Patients with mild to moderate renal or hepatic impairment.
Populations for whom use is not recommended (if applicable): Children < 16 years of age (tablets); Women attempting to conceive; Patients with advanced renal disease.
Populations for whom use is contraindicated: Known hypersensitivity to meloxicam or other NSAIDs; History of aspirin-sensitive asthma; Peri-operative pain in the setting of CABG surgery; Active gastrointestinal bleeding or peptic ulceration; Third trimester of pregnancy; Severe heart failure; Severe hepatic or non-dialysed severe renal failure.

Age-related eligibility rules:

  • Minimum Age: 2 years of age for specific pediatric indications (oral suspension form).
  • Older Adults (Geriatric): Use is permitted but officially requires caution due to the documented increased risk of serious adverse reactions.

Pregnancy and lactation eligibility status (if explicitly documented):

  • Third Trimester: Contraindicated from 30 weeks gestation and later.
  • Second Trimester: Restricted use is stated from 20 to 30 weeks gestation.
  • Lactation: Regulatory guidance requires a decision on whether to discontinue nursing or discontinue the drug, as meloxicam is present in human milk.

Connection to the overall eligibility profile: Official regulatory documents define who can and cannot use the medicine by establishing absolute contraindications based on severe organ dysfunction or allergic history. These boundaries also specify approved populations, such as specific age thresholds for pediatric use, and detail necessary restrictions for vulnerable groups like the elderly or those with chronic cardiovascular conditions, ensuring use remains within formally acceptable safety parameters.

What should I know about interactions with other medicines?

Meloflex (Meloxicam) can interact with several medicinal products and substance categories, primarily affecting blood clotting, blood pressure, and renal function. Concomitant use with other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), including analgesic doses of aspirin, is generally not recommended due to an increased risk of gastrointestinal bleeding and ulceration.

Potential Drug Interactions

Interacting Product Category Documented Interaction Mechanism or Result
Anticoagulants (e.g., warfarin), Antiplatelet agents, SSRIs/SNRIs Increased risk of bleeding and hemorrhage. Co-administration requires mandatory monitoring.
Diuretics (e.g., furosemide, thiazides) May reduce the diuretic and natriuretic effect; increased risk of worsening renal function.
ACE Inhibitors, Angiotensin Receptor Blockers (ARBs) May diminish the antihypertensive effect; increased risk of renal function deterioration, especially in high-risk patients.
Lithium Meloflex can increase lithium plasma levels, potentially leading to toxicity. Serum lithium levels must be monitored.
Methotrexate May increase methotrexate plasma concentrations, leading to enhanced toxicity.
Cyclosporine Increased risk of nephrotoxicity. Renal function must be closely monitored.

The oral suspension formulation of Meloflex is specifically contraindicated with Sodium Polystyrene Sulfonate due to the reported risk of intestinal necrosis. Use of Meloflex in the third trimester of pregnancy is not recommended due to the risk of premature closure of the fetal ductus arteriosus.

Mechanism of Action

Meloflex's action is governed by its mechanism as a preferential cyclo-oxygenase-2 (COX-2) inhibitor, a molecular strategy that modulates the eicosanoid signaling pathway.


Enzymatic Control of Inflammatory Mediators

The drug's primary mechanism involves the non-covalent inhibition of the COX-2 enzyme, which is highly upregulated at sites of tissue damage and is responsible for synthesizing pro-inflammatory prostanoids, such as Prostaglandin E₂. This action affects systems where chemical mediators dominate, resulting in a reduction of prostanoid synthesis rate and concentration.


Modulation of Nociceptive and Thermoregulation Signaling

By blocking COX-2, meloxicam modifies early molecular steps that shape systemic physiological outcomes. The resulting reduction of Prostaglandin E₂ directly decreases the chemical sensitization of peripheral pain receptors (nociceptors). Centrally, the mechanism causes a reduction of prostaglandin concentration in the hypothalamus. These adjustments reflect the mechanism's action on nociceptor sensitization and central thermoregulation pathways.


Mechanistic Constraint on Homeostasis

The drug's mechanism is inherently constrained by its dose-dependent activity against the constitutive COX-1 enzyme. Although preferential, higher systemic concentrations of meloxicam engage the COX-1 mechanism more significantly, which affects pathways responsible for producing homeostatic prostanoids necessary for gastric mucosal protection and platelet function. This engagement with COX-1 activity reflects a reduction in the drug's preferential inhibition profile.

Dosage and Administration Information

Meloflex (meloxicam) is officially administered via either the oral route (tablets, capsules, or suspension) or by intravenous (IV) injection for systemic effect. The core principle for its administration is the use of the lowest effective dose for the shortest duration. The standard dosing regimen is once daily across all approved forms and routes.

For chronic inflammatory conditions, the typical adult oral dose for tablets or suspension begins at 7.5 mg once daily and may be adjusted up to a maximum of 15 mg per day. The oral forms can generally be taken without regard to the timing of meals. If an oral dose is missed, the patient should take only the next scheduled dose at the usual time and not take a double dose to compensate.

The solution for injection is used for managing acute moderate-to-severe pain, with a standard dose of 30 mg administered once daily. This administration must be carried out as a rapid intravenous bolus over 15 seconds and requires the patient to be adequately hydrated prior to injection.

Specific patient populations require dosage modifications. The maximum oral daily dose is restricted to 7.5 mg for adult patients undergoing hemodialysis. For pediatric use in Juvenile Rheumatoid Arthritis (JRA), the dose is calculated by weight (e.g., 0.125 mg/kg for children 2 years of age or older), but must not exceed 7.5 mg per day.

Recent Clinical Evidence

Research Evidence: Overview of Studies

Overview of Clinical Trials

Research has examined the effects of the compound, which is thought to be involved in certain inflammatory pathways, and explored whether it may influence symptoms in patients with advanced refractory conditions.

  • Phase III Trials: Large-scale research sought to investigate Meloflex's use, often in combination with other agents, in mitigating the signs and symptoms of disease. Studies examined whether the combination was associated with changes in pain, inflammation, and flare-up frequency.
  • Trial Goals: The overall goal of the trials was to establish the compound's clinical profile across diverse patient groups, suggesting its use was examined in the context of primary treatment options for certain conditions.

Focus on Specific Populations and Long-Term Data

Mild Symptoms

Studies have investigated whether this treatment may be associated with a change in symptoms in people with mild forms of the condition, focusing on early intervention.

Long-Term Use

Research has evaluated the compound's safety profile during long-term use and compared it to older treatments. These studies explored whether the drug was associated with a change in disease progression markers over time.

Combined Therapy

Research has focused on the compound's use in combination with existing treatments, such as a combined approach with Drug Z, which was studied to determine if it had an influence on patient prognosis.


Safety Parameters and Liver Function

The compound was studied for managing the condition in various patient groups. Research has examined the use of Meloflex in people with liver impairment, and studies specifically evaluated the compound’s safety parameters and pharmacokinetic profile in this population.

Frequently Asked Questions (FAQ)

Common questions about Meloflex (FAQ)

Q: Is it normal to feel a little dizzy after taking Meloflex?

A: Official product information lists dizziness as a common adverse reaction associated with taking Meloflex. A common reaction is defined as one that occurs in at least 1 out of every 100 people who use the medication. Regulatory warnings indicate that caution should be exercised if nervous system effects like dizziness occur, particularly when operating machinery.

Q: Is weight gain a potential side effect of Meloflex?

A: The drug’s official side effect profile lists fluid retention, known as oedema (generalized swelling), as a common reaction. Unexplained or sudden weight changes may be a symptom of fluid retention. Rapid or unexplained weight changes are among the serious adverse events that regulatory guidance recommends reporting to a healthcare provider.

Q: Can Meloflex cause changes in sleep patterns?

A: Yes, official regulatory documents list potential adverse effects on the nervous system. These documented effects include insomnia, which is difficulty falling or staying asleep, and abnormal dreaming. These are potential side effects that may be reported during treatment.

Q: Are there any long-term side effects associated with Meloflex use?

A: According to the official warnings, the risk of serious cardiovascular thrombotic events (like heart attack or stroke) may increase with the duration of use. Official documents also indicate that long-term use is associated with potential serious effects on the kidneys and liver.

Q: What foods or drinks should be limited while taking Meloflex?

A: Official product information cautions against the use of alcohol because combining it with Meloflex can significantly increase the risk of serious gastrointestinal adverse events, such as bleeding, ulceration, or perforation of the stomach or intestine.

Q: Is Meloflex habit-forming or addictive?

A: Meloflex (Meloxicam) is a prescription-strength medicine. As a Non-steroidal anti-inflammatory drug (NSAID), it is not a scheduled controlled substance, which is the regulatory classification for drugs with established potential for abuse or dependence.

Q: Can Meloflex cause an allergic reaction?

A: Yes, Meloflex carries a warning that it can cause a severe allergic reaction. This medication is formally contraindicated (should not be used) in patients with known hypersensitivity (such as anaphylactic reactions) to meloxicam, aspirin, or other NSAIDs. Use in people with known hypersensitivity is restricted due to the potential for severe allergic reactions, including anaphylaxis.

Q: Is headache a common side effect when starting Meloflex?

A: Headache is included in the list of common adverse reactions noted in official documents. A common reaction means it has been reported to occur in 1% or more of the patients participating in clinical studies.

Q: Does taking Meloflex affect the results of any common lab tests?

A: Official information states that the use of this drug may be associated with documented abnormalities in liver function tests and renal (kidney) function tests. These findings may require monitoring.

Q: Why do some people experience stomach upset with Meloflex?

A: The drug’s mechanism is defined as a preferential cyclo-oxygenase-2 (COX-2) inhibitor. However, official documents note that at higher concentrations, it may also engage the COX-1 enzyme, which is responsible for producing compounds necessary for protecting the stomach lining (gastric mucosal protection). This action can lead to stomach upset or irritation.

Q: How is Meloflex eliminated from the body?

A: According to the pharmacokinetic data, Meloflex is primarily eliminated through a process called extensive hepatic biotransformation (metabolism in the liver). It is converted into inactive compounds that are then excreted almost equally through the urine and the faeces.

Q: Are there any known long-term studies on the safety of Meloflex?

A: Yes, official regulatory reviews confirm that research has been conducted to specifically evaluate the compound's safety profile during long-term use in its approved populations and compared it to older, traditional treatments.

Q: Why is Meloflex sometimes described as a selective medication?

A: Meloflex is described as a preferential or selective medication because its primary physiological action is as a preferential cyclooxygenase-2 (COX-2) inhibitor. This means it is designed to target the COX-2 enzyme—which is responsible for inflammation—more strongly than the COX-1 enzyme.

Q: Can Meloflex be used by people with asthma?

A: Meloflex is contraindicated (should not be used) in people who have a history of aspirin-sensitive asthma or other allergic-type reactions after taking aspirin or other NSAIDs. Use in patients with a history of aspirin-sensitive asthma is restricted due to the potential for severe allergic reactions.

Q: What is the shelf life of Meloflex?

A: The shelf life for Meloflex is determined by the manufacturer based on stability data and is found on the packaging. This is typically in the range of 24 to 36 months for different formulations, provided the medication is stored correctly according to the label.

Q: Do other ingredients in the Meloflex pill besides the active one cause reactions?

A: Regulatory documents include warnings about non-active ingredients in certain formulations. For example, the oral suspension formulation is specifically contraindicated for use with a bowel preparation medication (Sodium Polystyrene Sulfonate) due to the reported risk of intestinal necrosis.

Q: Has Meloflex ever been recalled for safety reasons?

A: The drug itself has not been recalled for inherent safety flaws. However, the FDA has issued a Class I recall (the most urgent type) for specific lots where bottles of a different medication were mistakenly labeled as Meloflex tablets due to a manufacturing mix-up.

Q: Are there reports of mood changes linked to Meloflex?

A: Official side effect lists include reports of nervous system effects that can impact mood or mental state. These documented effects include anxiety, irritability, confusion, or instances of mild depression.

Q: Does Meloflex affect blood sugar levels?

A: Yes, official drug interaction warnings indicate that Meloflex may affect blood sugar levels when combined with certain medications. For instance, when used with specific drugs for diabetes, there may be an increased risk of low blood sugar (hypoglycemia).

Q: Why is the official guidance so cautious about Meloflex use in certain heart conditions?

A: The official guidance includes a formal warning that NSAIDs like Meloflex may increase the risk of serious cardiovascular thrombotic events, including myocardial infarction (heart attack) and stroke. This is the primary basis for the required caution in patients with existing heart conditions or risk factors.

Q: Is Meloflex a prescription-only medicine?

A: Yes, Meloflex (Meloxicam) is classified as a prescription drug by regulatory agencies. It is not available for purchase over-the-counter in its approved tablet, capsule, or injection forms.

Q: Does Meloflex have a generic version available?

A: Yes, the active ingredient in Meloflex, meloxicam, is widely available in generic versions as a prescription product. Generic meloxicam is listed in official drug registries as an alternative to the brand-name product.

Q: What is the difference between Meloflex and common over-the-counter pain relievers?

A: The key regulatory-defined difference is in the mechanism of action. Meloflex is categorized as a preferential cyclo-oxygenase-2 (COX-2) inhibitor. Many common over-the-counter NSAID pain relievers are non-selective inhibitors, meaning they affect both the COX-1 and COX-2 enzymes almost equally.

Q: How long does it typically take for Meloflex to start working?

A: Pharmacokinetic data indicates the time it takes for the drug to reach its maximum concentration in the body. For the oral suspension, maximum plasma concentrations are typically reached within 2 hours, while the solid oral dosage forms (tablets and capsules) generally reach maximum concentration within 5 to 6 hours.

Q: Is there a risk of interaction between Meloflex and blood pressure medication?

A: Yes, regulatory documents list interactions with various blood pressure medications, including ACE Inhibitors, ARBs, Diuretics, and Beta-blockers. These interactions may diminish the antihypertensive effect of the blood pressure medication or increase the risk of worsening kidney function.

Q: Are there different strengths or dosages of Meloflex available?

A: Yes, official product documents list that Meloflex is available in different strengths and forms. These include 7.5 mg and 15 mg tablets for oral use, and a 30 mg solution for intravenous injection.

Q: Can I have alcohol while taking Meloflex?

A: The official product information specifically warns that consuming alcohol while taking Meloflex increases the risk of serious gastrointestinal adverse events, such as bleeding, ulceration, or perforation. This risk is documented in regulatory warnings.

Q: How can I tell the difference between a minor side effect and a serious one from Meloflex?

A: Regulatory information separates side effects into Common Reactions (e.g., headache, dizziness, nausea) and Serious Adverse Reactions. Serious reactions are those that may signal life-threatening events, such as chest pain, shortness of breath, slurred speech, or bloody/black stool, which the label indicates warrant immediate medical attention.

Q: What should I do if I accidentally take an extra dose of Meloflex?

A: The official Overdosage section provides guidance on what to expect. Symptoms of an overdose may include drowsiness, nausea, vomiting, or stomach pain. The official guidelines for the Overdosage section indicate the need to seek emergency medical attention.

How should Meloflex be stored and disposed of?

How to Store and Dispose of Meloflex (Meloxicam)

Meloxicam tablets must be stored according to official regulatory requirements to ensure product quality and safety.


Storage Conditions

  • Temperature: Store at Controlled Room Temperature, specifically between 20 C and 25 C (68 F to 77 F). Transient excursions up to 30 C are permitted.
  • Environment: The product must be kept in a tight container and stored in a dry place.
  • Safety: The medication must be kept strictly out of the reach of children.

Disposal Instructions

Disposal of unused or expired Meloflex should follow established regulatory guidelines.

  • Method: The preferred method is to use a drug take-back program (e.g., pharmacy or community collection site).
  • Prohibition: The medication must not be flushed down the toilet or poured down the sink.
  • Alternative: If a take-back option is unavailable, the product should be mixed with an undesirable substance (such as dirt or cat litter), sealed in a bag, and discarded with household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Meloflex found in:

A-Z Index: